SCL Science Inc. (KOSDAQ:246960)

South Korea · Delayed Price · Currency is KRW

1,945.00

+111.00 (6.05%)

At close: Aug 11, 2026

-25.90% (1Y)

Market Cap	66.16B -25.8%
Revenue (ttm)	27.40B +366.8%
Net Income	-3.17B
EPS	-92.99
Shares Out	34.01M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	141,991
Open	1,834.00
Previous Close	1,834.00
Day's Range	1,794.00 - 1,988.00
52-Week Range	1,389.00 - 3,250.00
Beta	0.49
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About SCL Science

SCL Science Inc. produces medical hemostatic agents using biomimetic technology. Its products include BiMM (Bio-inspired Medical Materials) that reacts immediately with blood; Endoseal, which is used for specialized indication of gastrointestinal bleeding; InnoSeal, a hemostatic agent that is used in various surgical fields, such as cardiology, radiology, and neurosurgery; Jelly Seal, a hemostasis and sealing products; STOP, a non-bleeding intravascular injection; Film that prevents leakage at intestinal and vascular anastomosis sites; InnoLOCK... [Read more]

Industry Orthopedic, Prosthetic, and Surgical Appliances and Supplies

Founded 2010

Country South Korea

Stock Exchange KOSDAQ

Ticker Symbol 246960

Full Company Profile

Financial Performance

In 2025, SCL Science's revenue was 22.01 billion, an increase of 364.64% compared to the previous year's 4.74 billion. Losses were -3.93 billion, 5.47% more than in 2024.

Financial Statements